A new treatment for rare muscular disease
UC researchers present findings that could give patients with Pompe disease a better quality of life
Rare diseases are sometimes the most difficult to treat because of a lack of research and fewer participants to study.
An example would be those who have Pompe disease, a genetic condition when a body can't make a protein that breaks down a complex sugar, called glycogen, for energy. Too much glycogen builds up and damages muscles and organs. The disease causes muscle weakness and trouble breathing and can affect the heart and muscles.
In the case of Pompe disease, however, University of Cincinnati researchers have found a newer, more effective treatment for the rare condition that could become the new standard of care.
Hani Kushlaf, MD, an associate professor in both the Department of Neurology and Rehabilitation Medicine and the Department of Pathology and Laboratory Medicine at UC and principal investigator of a study led at UC, will present findings on this new treatment virtually at the American Academy of Neurology on April 20.
Hani Kushlaf, MD, an associate professor in both the Department of Neurology and Rehabilitation Medicine and the Department of Pathology and Laboratory Medicine at UC and principal investigator of the study. Photo/UC Health
Kushlaf, a UC Health physician, says Pompe disease affects about 1 in 40,000 people in the United States. It can impact children, but it can also present later in life as well. Left untreated, it can result in progressive loss of function of muscles in limbs and respiration leading to the need for wheelchair use and respiratory support.
“In this clinical trial, we tested a new drug, or enzyme replacement therapy (avalglucosidase alfa), to see if it was more effective and safer than the currently approved therapy, also an enzyme replacement therapy, in patients with late-onset Pompe disease,” he says. “It turns out that it is safer and more effective than the current FDA-approved therapy. This new enzyme will likely become the standard of care for patients with the disease and has already been submitted for Food and Drug Administration approval. This is a big deal for patients with this rare disease, as t-PA was for stroke.”
These results are extremely promising for finding a new and effective treatment for [Pompe] disease.
Hani Kushlaf, MD
This study was double-blinded, meaning neither the participants nor the researchers knew which treatment was being administered via an infusion. In 51 patients who received the new treatment, researchers saw an improvement in respiratory muscle function, endurance and muscle strength, in addition to an overall better quality of life, when compared to patients on the current standard of care therapy.
“These results are extremely promising for finding a new and effective treatment for this disease,” adds Kushlaf, who is also a member of the UC Gardner Neuroscience Institute. “With these results, we can take the next steps in having it used widely in this patient population, improving their outcomes and giving them a better life.”
Featured photo of lungs by iStock.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up to date on all UC's COVID-19 stories, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
The trial is sponsored by the pharmaceutical company Sanofi. Kushlaf belongs to an author group appointed by Sanofi and is responsible for disseminating the findings of this trial.
Related Stories
First-ever Gen-Z Insights event hosted by UC NEXT Innovation...
April 19, 2024
In academia, the intersection of innovation, collaboration and the fresh perspectives of the University of Cincinnati NEXT Innovation Scholars (NIS) holds immense promise. As a multi-disciplinary student group of innovators, the program balances university, corporate and non-profit partners. NIS students are driven by curiosity, passion, future creation and pursuing innovation, fostering a community of forward-thinkers poised to tackle tomorrow's challenges today. Recently, these young visionaries hosted an inaugural Gen-Z Insights showcase event at the UC 1819 Innovation Hub. The packed room of attendees included 1819 corporate partners such as Kao and Main Street Ventures and distinguished faculty and staff members. All were eager to hear and learn more from NIS scholars and the industry projects they worked on throughout the year.
Alabama.com: How a new self-test for HPV could be a game changer
April 19, 2024
The University of Cincinnati's Leeya Pinder was featured in an Alabama.com/Reckon article about how self-testing for HPV could make preventative care more accessible to those facing the most barriers.
UC's CECH recognizes students, faculty and staff for outstanding...
April 19, 2024
In the early weeks of April 2024, UC's College of Education, Criminal Justice, Human Services, and Information Technology recognized and celebrated students, faculty and staff achievements annual Outstanding Student Awards and All College Awards ceremony, the latter of which awarded both Faculty and Staff Awards and the college's Golden Apple Awards.